The impact of moderate and severe asthma exacerbations on quality of life: a post hoc analysis of randomised controlled trial data

Author:

Briggs Andrew,Nasser Shuaib,Hammerby EvaORCID,Buchs Sarah,Virchow J. Christian

Abstract

Abstract Background This paper reports the duration of moderate and severe exacerbations in patients with house dust mite induced allergic asthma and the impact on patients’ quality of life. Methods Post-hoc analyses were conducted using data collected during a phase III multi-national trial (MT-04) that investigated time to moderate or severe asthma exacerbation among 485 patients during withdrawal from inhaled corticosteroids. Patient diaries were analysed to ascertain duration of exacerbations. The impact on patients’ quality of life was measured by calculating utilities for five health states using the EuroQol-5 Dimension (EQ-5D-3L) and Asthma Quality of Life Questionnaire (AQL-5D). A regression analysis predicted the disutility of moving from ‘well controlled asthma’ to the other four health states: ‘partially controlled asthma’, ‘uncontrolled asthma’, ‘moderate exacerbation’ and ‘severe exacerbation’. Results Two hundred four patients experienced exacerbations. Moderate and severe exacerbations involved statistically significant reductions in lung function compared to the constant peak expiratory flow observed for patients without exacerbations. Lung function decline occurred for 28 days, decreasing approximately 14 days before an exacerbation followed by a return to baseline over 14 days. Asthma symptoms, the use of short-acting β2-agonists, and frequency of nocturnal awakening all increased, starting 10–14 days before an exacerbation, and returned to baseline within 10–28 days following exacerbations. Compared to ‘well controlled asthma’, the disutility of having a ‘moderate exacerbation’ ranged from − 0.0834 to − 0.0921 (EQ-5D-3L) and from − 0.114 to − 0.121 (AQL-5D); and of having a ‘severe exacerbation’ from − 0.115 to − 0.163 (EQ-5D-3L) and from − 0.153 to − 0.217 (AQL-5D), depending on the length of the observation period. Conclusions The impact of moderate and severe exacerbations in house dust mite induced allergic asthma extends 14 days before and 28 days after the peak exacerbation event. The impact of exacerbations on patients’ health-related quality of life (HRQoL) continues long after their occurrence.

Funder

ALK-Abello A/S

Publisher

Springer Science and Business Media LLC

Subject

Health Information Management,Health Informatics

Reference34 articles.

1. Medical Review (2015). Allergens and allergic asthma. Asthma and allergy Foundation of America [cited Feb 05 2018]. Available from: http://www.aafa.org/page/allergic-asthma.aspx.

2. Nathan, R. A. (2007). The burden of allergic rhinitis. Allergy and Asthma Proceedings, 28(1), 3–9.

3. Schatz, M. (2007). A survey of the burden of allergic rhinitis in the USA. Allergy., 62(Suppl 85), 9–16.

4. Sadatsafavi, M., & Fitzgerald, J. M. (2014). Economic burden of asthma [cited Feb 22nd 2018]. Available from: http://www.globalasthmareport.org/burden/economic.php.

5. Ivanova, J. I., Bergman, R., Birnbaum, H. G., Colice, G. L., Silverman, R. A., & McLaurin, K. (2012). Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. The Journal of Allergy and Clinical Immunology, 129(5), 1229–1235.

Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study;The Journal of Allergy and Clinical Immunology: In Practice;2024-09

2. Use of infection control measures in people with chronic lung disease: mixed methods study;ERJ Open Research;2023-11-30

3. Expert Consensus on SABA Use for Asthma Clinical Decision-Making: A Delphi Approach;Current Allergy and Asthma Reports;2023-11

4. Advancing precision medicine in asthma: Evolution of treatment outcomes;Journal of Allergy and Clinical Immunology;2023-10

5. Asthma Exacerbations: The Genes Behind the Scenes;Journal of Investigational Allergy and Clinical Immunology;2023-04-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3